Zynex, Inc. (ZYXI)

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (OTC Pink: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Zynex (ZYXIQ) To Contact Him Directly To Discuss Their Options

SAN FRANCISCO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against the former top executives of Zynex, Inc., whose common stock traded on the NASDAQ exchange under the symbol “ZYXI” prior to its suspension on Dec. 24, 2025 and subsequently traded over the counter as “ZYXIQ.” The lawsuit, captioned Beidel v.

ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (OTCMKTS: ZYXIQ). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Zynex's business, operations, and prospects, including allegations that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; and (3) the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; and (4) the Company's order growth was a result of illegal overbilling.

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Zynex, Inc. (“Zynex” or the “Company”) (OTC: ZYXIQ) between February 25 , 202 1 and December 15 , 202 5, inclusive. Should You Join The Zynex Class Action Litigation?

New class action for Zynex, Inc. (ZYXIQ) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options

ENGLEWOOD, Colo., Feb. 4, 2026 /PRNewswire/ -- Zynex, Inc. (ZYXIQ), an innovative medical device company specializing in non-invasive medical devices for pain management, announced it has for the first time entered into a provider agreement with Humana Inc. (NYSE: HUM), effective February 1, 2026.

ENGLEWOOD, Colo., Jan. 22, 2026 /PRNewswire/ -- Zynex, Inc. (ZYXIQ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today issued the following statement regarding the federal indictments of two former executives.

ENGLEWOOD, Colo. , Dec. 16, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation today announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring with the support of new financing from the Company's lenders.

Zynex, Inc. ( ZYXI ) Q3 2025 Earnings Call November 18, 2025 9:00 AM EST Company Participants Vikram Bajaj - Chief Financial Officer Steven Dyson - CEO & Director Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex Third Quarter 2025 Earnings Conference Call.

ENGLEWOOD, Colo. , Nov. 17, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025.

Zynex Inc (NASDAQ:ZYXI) said on Friday it has hired financial advisory firm Province LLC and formed a special board committee to evaluate a range of strategic alternatives. The company said Province will assist in reviewing options that include potential capital-raising, recapitalization and restructuring strategies.

ENGLEWOOD, Colo. , Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success.

ENGLEWOOD, Colo. , Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025.

Zynex Inc (NASDAQ:ZYXI) announced the appointment of Bret Wise to its Board of Directors. He will also serve as chair of the Audit Committee.